Biohaven Ltd. (BHVN) Stock Price & Analysis
Biohaven Ltd. (BHVN) fell 0.27% to USD 11.09 as of June 10, 2026 at 02:27 UTC, according to Nexqual real-time market data.
BHVN last closed at USD 11.12; the session ranged USD 10.69–12 on volume of 3,288,628 shares. Market capitalization is $1.67B, with a 52-week range of USD 7.48–18.57 (NYQ). Source: Nexqual, June 10, 2026 at 02:27 UTC.
Key Statistics (as of June 10, 2026 at 02:27 UTC)
| Price | USD 11.09 |
|---|---|
| Change | ▼ 0.27% (down) |
| Previous Close | USD 11.12 |
| Open | USD 11.24 |
| Day Range | USD 10.69 – 12 |
| 52-Week Range | USD 7.48 – 18.57 |
| Volume | 3,288,628 shares |
| Market Cap | $1.67B |
| Exchange | NYQ |
Technical Analysis (BHVN)
Nexqual's technical model rates BHVN "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 02:27 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 55.23 (neutral) |
| vs SMA50 | Above (USD 9.85) |
| MACD | 0.41 (positive) |
Analyst Ratings (BHVN)
Wall Street analysts rate BHVN "Buy" based on 17 analysts, with a mean price target of USD 21.71 (range USD 9–50), per Nexqual as of June 10, 2026 at 02:27 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 17 |
| Mean Target | USD 21.71 |
| High Target | USD 50 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 14 / 5 / 0 |
Earnings (BHVN)
| Next Earnings Date | 2026-05-04 |
|---|---|
| EPS Estimate | USD -0.61 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.69 vs est -0.76 ▲ beat |
| 2025-12-31 | USD -0.9 vs est -0.96 ▲ beat |
| 2025-09-30 | USD -1.47 vs est -1.54 ▲ beat |
| 2025-06-30 | USD -1.63 vs est -1.57 ▼ miss |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Financials & Fundamentals (BHVN)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -333.00% |
| Debt / Equity | 220.99 |
| Current Ratio | 7.41 |
| Total Cash | $347.82M |
| Total Debt | $286.18M |
| Free Cash Flow | $-379.37M |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Financial Health Score (BHVN)
Nexqual rates Biohaven Ltd.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:27 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Weak — $348M cash vs $286M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$594M |
| Efficiency | Critical — ROE -333%, ROA -83.4% |
Ownership (BHVN)
| Insider Ownership | +11.08% |
|---|---|
| Institutional Ownership | +97.64% |
| Shares Outstanding | 150.56M |
| Float | 124.00M |
| Short % of Float | +21.47% |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Leadership (BHVN)
Biohaven Ltd. is led by Vladimir Coric (age 54), Chairman & CEO, per Nexqual as of June 10, 2026 at 02:27 UTC.
| Chairman & CEO | Vladimir Coric (age 54) |
|---|---|
| Chief Financial Officer | Matthew Buten (age 64) |
| Chief Scientific Officer | Bruce D. Car DACVP (age 63) |
| Senior Vice President of Clinical Operations | Kimberly Gentile (age 59) |
| Senior Director of Regulatory Affairs & Operations | Deb Young |
Major Backers & Investors (BHVN)
Notable institutional backers of Biohaven Ltd. include Janus Henderson Group PLC, Suvretta Capital Management, LLC, Stifel Financial Corporation, according to Nexqual as of June 10, 2026 at 02:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Janus Henderson Group PLC | 11.65% |
| Suvretta Capital Management, LLC | 6.83% |
| Stifel Financial Corporation | 6.6% |
| Infinitum Asset Management, LLC | 4.15% |
| JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund | 3.32% |
| TCG Crossover Management, LLC | 3.08% |
| Royalty Pharma Sub-manager, LLC | 1.95% |
| Shaw D.E. & Co., Inc. | 1.89% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.93% |
| State Street | 7.22% |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
From Biohaven Ltd.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.
- The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors.
- In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBIO | BridgeBio Pharma, Inc. | USD 67.68 | ▲ 0.1% |
| DNLI | Denali Therapeutics Inc. | USD 20.79 | ▲ 6.51% |
| ARVN | Arvinas, Inc. | USD 7.21 | ▼ 2.83% |
| MDGL | Madrigal Pharmaceuticals, Inc. | USD 476.89 | ▼ 2.07% |
| CRNX | Crinetics Pharmaceuticals, Inc. | USD 34.97 | ▲ 6.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:27 UTC. This page is informational and not investment advice.